Introduction
In the era of precision medicine, the ability to select the most effective drug for a specific genetic mutation is paramount. However, the necessary biological data is often fragmented across multiple disparate databases, such as the Cancer Genome Interpreter (CGI) and Drug Target Commons (DTC). While technologies like Linked Data (RDF) facilitate machine-to-machine communication, they do little to alleviate the "cognitive load" placed on researchers who must manually synthesize heterogeneous information.
Furthermore, biomedical data is rarely perfect; it is frequently characterized by missing information, inconsistencies between sources, and varying levels of clinical credibility. Traditional tools often hide these nuances, potentially leading to suboptimal clinical decisions. To address this, we developed MediSyn, an uncertainty-aware visualization tool designed to help researchers navigate the "messy" reality of clinical and experimental data.
The MediSyn Framework
MediSyn utilizes a web-based, matrix-based layout where columns represent targets (mutations or wild-type genes) and rows represent drugs. This structure is inherently scalable and makes knowledge gaps—represented as empty cells—immediately obvious to the user.
The core innovation of MediSyn lies in its overlaid layers. Rather than presenting datasets side-by-side, the system integrates them within the same visual space. Following established principles of visual encoding, the system uses Hue (green for responsive, red for resistant) to indicate clinical drug-mutation effects from CGI, and Length/Position (bar charts) to represent quantitative potency and evidence levels from DTC. Every data point includes provenance links to original publication sources (DOIs), allowing for immediate verification.
Data Integration and the Challenge of Heterogeneity
MediSyn synthesizes two major manually curated datasets to provide a comprehensive view of the drug-target landscape:
- Cancer Genome Interpreter (CGI): Focuses on clinical biomarkers and drug responses across various tumor types.
- Drug Target Commons (DTC): Provides quantitative bioactivity data (such as $IC_{50}$ or $K_d$ values) from experimental assays.
By integrating 536 mutations, 258 drugs, and over 2,300 drug-target relations, MediSyn transforms complex tabular data into a visual map that highlights both consensus and conflict.
Visualizing Uncertainty and Conflict
Unlike systems that attempt to "clean" data by resolving conflicts behind the scenes, MediSyn treats inconsistency as a salient feature. For instance, a cell might display a red "Resistant" background from CGI overlaid with a "Highly Potent" black bar from DTC. This visual dissonance alerts researchers that a drug's efficacy may be context-dependent or debated in the literature.
Additionally, the inclusion of a "Wild-Type" column alongside mutations allows researchers to quickly identify potential toxicity. Drugs that show high potency against both the mutation and the healthy wild-type gene may pose a higher risk of adverse effects, a critical consideration in drug selection and repurposing.
Evaluation and Key Findings
A study conducted with six domain experts compared MediSyn against the standard practice of searching individual database websites. The results demonstrated significant improvements in both performance and user experience:
- Efficiency: Researchers were over 3x faster at selecting appropriate drugs using MediSyn (averaging 1m 57s) compared to the baseline (6m 22s).
- Usability: MediSyn received high marks for ease of use (7/7) and overall satisfaction (5.5/7).
- Discovery: The tool facilitated "serendipitous discovery," such as identifying Axitinib as a potential treatment for the T315I mutation—a finding supported by clinical literature but difficult to synthesize from raw tables.
Conclusion and Future Work
MediSyn demonstrates that making data uncertainty visible can actually improve decision-making efficiency. While the current matrix layout is highly effective for two to three datasets, future work will explore summary views to prevent visual clutter as more sources are added. Additionally, experts have noted the need to integrate patient-specific context—such as age and treatment history—to further bridge the gap between experimental data and clinical application.
Summary updated